文献速递妇产影像介入US

超声引导硬化治疗卵巢子宫内膜异位囊肿:系统综述与荟萃分析

Ultrasound-guided sclerotherapy for the treatment of ovarian endometrioma: an updated systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2021-09-27

汇总技术成功率为98.3%,复发率13.8%,疼痛缓解率85.9%,妊娠率37.6%,主要并发症率1.7%。硬化时间>10分钟者复发率显著低于≤10分钟者(直接比较OR 0.2,p=0.015),且与手术相比可提高妊娠率(OR 2.0,p=0.042)。

要点

  • 超声引导硬化治疗卵巢子宫内膜异位囊肿技术成功率高、主要并发症率低。
  • 硬化时间>10分钟可降低复发率,且不增加主要并发症。
  • 与手术相比,硬化治疗可提高妊娠率,但需RCT进一步验证。

局限性

  • 未来需要随机对照试验比较超声引导硬化治疗与手术的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine the efficacy and safety of ultrasound (US)-guided sclerotherapy for the treatment of ovarian endometrioma through a systematic review and meta-analysis.

METHODS: MEDLINE and EMBASE databases were searched for studies reporting outcomes in patients with endometrioma who were treated with US-guided sclerotherapy. Meta-analyses of recurrence, pain resolution, pregnancy, technical success, and complication rates were analyzed. Subgroup analyses were conducted regarding the indwelling time of sclerotherapy (≤ 10 min vs > 10 min).

RESULTS: Twenty-eight studies (1301 patients) were included. The pooled technical efficacy was 98.3%. The pooled estimates of recurrence, pain resolution, and pregnancy rate were 13.8%, 85.9%, and 37.6%, respectively. The pooled major complication rate was 1.7%. A sclerotherapy time > 10 min had a lower pooled recurrence rate than a time ≤ 10 min (11.2% vs 20.9%; p = 0.106). Direct comparisons showed that the recurrence rate was significantly lower with sclerotherapy > 10 min than with sclerotherapy ≤ 10 min (OR, 0.2; p = 0.015). Regarding pregnancy rates, sclerotherapy of > 10 min showed no significant difference compared with sclerotherapy of ≤ 10 min (35.9% vs 38.8%; p = 0.664). Direct comparisons with surgery showed that sclerotherapy increased the pregnancy rate compared with surgery (OR, 2.0; p = 0.042). There was no significant difference in AMH level before and after sclerotherapy (p = 0.951). There was no significant difference in major complication rates between sclerotherapy > 10 min and ≤ 10 min (p = 0.837).

CONCLUSION: US-guided sclerotherapy seems to be an effective and safe therapeutic option regarding recurrence, pain resolution, and pregnancy for patients with ovarian endometrioma.

KEY POINTS: • US-guided sclerotherapy seems to be an effective and safe therapeutic option regarding recurrence, pain resolution, and pregnancy for patients with ovarian endometrioma. • Sclerotherapy of more than 10 min had a lower recurrence rate than sclerotherapy less than or equal to 10 min. There was no significant difference in major complication rates between sclerotherapy of > 10 min and ≤ 10 min. • Future randomized controlled trials are warranted to compare the outcomes of US-guided sclerotherapy with surgery.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim GH, Kim PH, Shin JH, et al. Ultrasound-guided sclerotherapy for the treatment of ovarian endometrioma: an updated systematic review and meta-analysis. Eur Radiol. 2021. PMID: 34580747. doi:10.1007/s00330-021-08270-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。